We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Regenerative Medicine to Benefit from Automated Cell Culture Platform

By LabMedica International staff writers
Posted on 01 Aug 2011
A publication in the rapidly expanding field of regenerative medicine described the development of an automated liquid-handling cell-culture platform for isolating, expanding, and characterizing human primary cells. More...
The new system will facilitate the production of cells and cell-based products that contribute to the regeneration or repair of damaged and degenerated tissues and organs.

The heart of the automated system is the Roche (Basel, Switzerland) high-throughput Cellavista Imaging System for noninvasive measurement of cell expansion and fluorescence measurement of cell quality.

The Cellavista Imaging System was combined with a liquid-handling robot produced by Tecan (Männedorf, Switzerland). Together these instruments are able to automatically load and unload the centrifuge module, operate a programmable homogenizer, and monitor clean air hood ventilation for purity level four requirements (VDI 2083) and class 1000 (US Federal Standard 209). The Cellavista Imaging component measures cell expansion using bright field and fluorescence detection with multiwell plates, chamber slides, or RoboFlasks.

The platform was tested by investigators at Zurich University of Applied Sciences (Switzerland) who demonstrated that the automated liquid-handling cell-culture platform could be used effectively to isolate, expand, and characterize human primary cells (e.g., from intervertebral disc tissue) with results that were comparable to the manual procedure. Specifically, no differences could be observed for cell yield, viability, aggregation rate, growth rate, and phenotype. All steps-from the enzymatic isolation of cells through biopsy to final quality control were performed completely by the automated system, which was possible due to the novel tools that were incorporated into the platform. These findings were published in the June 2011 issue of the Journal of the Association of Laboratory Automation.

The authors predicted that this type of automated cell handling system would make a great contribution to regenerative medicine, since, “Only automated systems can provide safe, reproducible, effective, and affordable cell-based products that are able to meet legislative needs, such as good manufacturing practice (GMP) requirements.”

Related Links:

Roche
Tecan
Zurich University of Applied Sciences



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.